A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)

1. A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)

2. LMI’s tasks/obkectives • LMI should be the obvious association (choice) both for the multinational companies and the smaller Norwegian entrepreneurs operating in the pharmaceutical / life science area • The associations objective is to protect the member companies’ interests related to

3. LMI in brief • 52 members per December 1st 2012 • More than 80 % of the total pharmaceutical sales • Membercompaniesemployabout 4 000 people • Cooperation and dialogue partner for theauthorities • Liaison betweenindustry and authorities

4. Drug sales in Norway 2012 • 18.6 billion (PRP) • An increase of 0.3 in the PRP • 12 billion (AIP) • Growth of 1.4 percent in the DDD • 9.1 billion in reimbursement • 71 percent of expendituresfinanced by thepublic • 25 percent VAT on all medicines • Low rates • Drugconsumption is belowaverage in the Nordic countries

5. Organisation of the LMI Group • LMIs management is funded by themembersthrough a service charge • Shareholders, board and management • 14 committees, whereemployees of memberfirmscontribute • Felleskatalogen AS and Farmastat AS areindependentsubsidiaries • The industry has 12 employees, Felleskatalogen has 5 and Farmastat has 6 employees

6. Vision and goal Vision • Medical advances for betterhealth Objectives / goals • Greatervisibility and a good and trustingrelationshipwiththeoutsideworld • Ensure thatthe Norwegian patientsgetquickaccess to medicalinnovations • Increaseresearch, production and business development at pharmaceutical area in Norway • Ensuring a goodframework for theindustry

7. Our business areas • Visibility / communications • Policy work / conditions • Organization • Member Services

8. Wealthcreation and visibility (1) • LMI would like to take a new and clearrole as a politicalinfluence, and contribute to a strongervisibility of thepharmaceuticalindustry'scontribution to society. • LMI will be a future-oriented trade organizationthat promotes business and health policy viewsonbehalf of themember-companies. In addition to protectindustryinterests, LMI willmaintain a strongfocusonthepatient and thepatients' rights.

9. Wealthcreation and visibility (2) • There is a need for increasedactivity and effortsrelated to thepromotion of research and industrialdevelopment in thepharmaceutical area in Norway, and a greaterextentassureneeds of small, established Norwegian companies. • LMI willmaintain a membership service of highquality.

10. Workingmethods • Visibility • Professional expertise and credibility • Dialogue and cooperationratherthanconflict • Participation in broaderhealth policy arenas • Networking • Dialoguewithalliance partners

11. Transparency and tidiness • Clear and binding framework for cooperationthroughagreements (RHF DNLF, NFF, NSF, FFO) • Updatedinternal and self-imposedrules (Rules for druginformation) • Industry internalawareness in relation to ethicalissues • The principle is that all interactionsshould be open, verifiable, and withstand a criticallight

12. Whatexpertise do LMI have? • Research and development - clinical trials • Approval of drugs / regulatory affairs • Price, reimbursement and revenue • Health Economics – Statistics • Drug Policy / Health Policy • Rules and regulations for marketing • Industry Information • Information - Press & Media • Public Affairs • Member Services and courses

13. Workingmethods